Report Highlights

The United States' Role in the Global Erythropoietin Supply Chain

The United States is the largest consumer and a leading manufacturing base for recombinant erythropoietin, anchored by Amgen's mammalian cell culture operations in Thousand Oaks, California and its Puerto Rico production network. Domestic output of epoetin alfa supplies US dialysis and oncology channels directly, while the country remains a net importer of finished biosimilar vials and prefilled syringes from European fill-finish partners. Trade flows therefore run in both directions: high-value biologic drug substance leaves US ports, and lower-cost finished product enters through Atlantic gateways and Puerto Rico's bonded warehouses.

Import dependency sits mainly in biosimilar supply rather than the originator franchise. Retacrit, the first US epoetin biosimilar approved in 2018, relies on Pfizer's multi-site manufacturing network, creating exposure to ocean freight, 2–8°C cold-chain handling, and customs clearance at the Port of New York and New Jersey. The strategic vulnerability is single-sourced drug substance: a disruption at one European bioreactor site would constrain a material share of US biosimilar epoetin volume within a single quarter.

Growth Drivers for Erythropoietin Trade and Production in the US

Rising chronic kidney disease prevalence, affecting roughly 15 percent of US adults, keeps ESA demand structurally rising across dialysis centers. Expansion of dialysis capacity by Fresenius Medical Care and DaVita adds treatment chairs that pull through injectable epoetin volumes, which in turn justifies incremental domestic fill-finish investment.

Import substitution is the second driver. Pfizer and Amgen are shifting finished-dose sourcing toward US-based lines ahead of pharmaceutical tariff exposure, while Medicare Part B reimbursement for biosimilars at average sales price plus a statutory add-on raises demand for qualified domestic supply. Puerto Rico's tax incentive regime for biologics production forms the third driver, attracting manufacturing capital that shortens the export route to mainland distribution.

Supply Chain Risks and Trade Barriers

Raw material dependency is the primary operational risk. Epoetin production relies on CHO cell lines, specialized cell culture media, and single-use bioreactor components sourced from a small group of global suppliers, and any interruption in glycosylation-critical inputs degrades product consistency. Cold-chain logistics add a second constraint, since refrigerated distribution from coastal ports to dialysis clinics leaves little tolerance for transit delays.

Trade barrier exposure centers on pharmaceutical tariffs. The Section 232 investigation into pharmaceutical imports and the 2025 US-EU framework capping most EU pharmaceutical tariffs at 15 percent create uncertainty for European-sourced biosimilar drug substance. Dollar-euro currency movements further erode the margin of imported finished product, which pressures biosimilar pricing in a market where reimbursement is already compressed.

Trade and Investment Opportunities in the United States

US-manufactured epoetin drug substance has an export opportunity in Latin America and parts of Asia, where dialysis capacity is expanding faster than domestic biologics production. Puerto Rico's manufacturing base and foreign-trade zone status position the island as a logistics hub for re-export to Caribbean and Latin American markets without mainland customs friction.

Inbound FDI into domestic fill-finish and contract development capacity represents the most commercially grounded opportunity. Contract manufacturers with validated cold-chain packaging lines can capture overflow from originator and biosimilar sponsors seeking to reduce tariff exposure, particularly where prefilled syringe capacity remains constrained.

Market at a Glance

Leading Market Participants

• Amgen
• Johnson & Johnson
• Pfizer
• CSL Vifor
• Fresenius Kabi
• Sandoz
• Akebia Therapeutics
• Teva Pharmaceutical Industries
• Biocon Biologics
• Mitsubishi Tanabe Pharma America

Regulatory and Trade Policy Environment

Epoetin products are regulated as biologics under the FDA biologics license pathway, and biosimilars follow the abbreviated route established by the Biologics Price Competition and Innovation Act of 2009. Interchangeability designation affects pharmacy-level substitution, while the ESA boxed warning on cardiovascular and thrombotic risk at higher hemoglobin targets continues to shape dosing protocols across all products.

Reimbursement is the dominant policy lever. The Medicare ESRD Prospective Payment System bundles ESA costs into the per-treatment payment for dialysis, and Medicare Part B covers biosimilars at average sales price plus a statutory add-on. Trade policy operates alongside this framework: USMCA governs Mexican and Canadian supply, Puerto Rico's Act 60 incentives support domestic biologics investment, and Section 232 tariff actions remain the principal uncertainty for imported finished product.

U.S. Erythropoietin Supply Chain Outlook to 2032

US supply chains will shift toward domestic fill-finish and regional drug substance capacity over the forecast period, as tariff exposure and cold-chain risk make single-country sourcing commercially untenable. Biosimilar penetration will rise steadily, and volume will migrate toward manufacturers that control multi-site redundancy rather than those dependent on a single European or Puerto Rican facility.

Technology changes will reshape comparative advantage. Long-acting and oral alternatives, including HIF-PHI agents, will reduce injectable epoetin demand in certain dialysis cohorts, while continuous bioprocessing in mammalian cell culture will lower unit costs for producers able to fund facility conversions. Suppliers that secure both biosimilar pricing position and flexible US capacity will hold the strongest position through 2032.